HC Wainwright Has Bullish Outlook for RVPH FY2024 Earnings

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPHFree Report) – Investment analysts at HC Wainwright boosted their FY2024 earnings per share (EPS) estimates for Reviva Pharmaceuticals in a research note issued on Wednesday, January 22nd. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($1.00) per share for the year, up from their previous forecast of ($1.04). HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($0.99) per share. HC Wainwright also issued estimates for Reviva Pharmaceuticals’ Q4 2024 earnings at ($0.25) EPS, Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.16) EPS and FY2025 earnings at ($0.82) EPS.

Several other analysts have also commented on RVPH. D. Boral Capital reissued a “buy” rating and set a $15.00 target price on shares of Reviva Pharmaceuticals in a research note on Tuesday, January 21st. Maxim Group upgraded Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a report on Friday, January 10th. Roth Capital raised Reviva Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 10th. Finally, Roth Mkm began coverage on Reviva Pharmaceuticals in a research report on Friday, January 10th. They issued a “buy” rating and a $7.00 price target for the company. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Reviva Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $11.40.

Read Our Latest Analysis on Reviva Pharmaceuticals

Reviva Pharmaceuticals Trading Up 1.1 %

Shares of NASDAQ RVPH opened at $1.91 on Friday. Reviva Pharmaceuticals has a twelve month low of $0.60 and a twelve month high of $4.83. The firm has a 50-day moving average of $1.71 and a two-hundred day moving average of $1.34. The company has a market capitalization of $63.87 million, a price-to-earnings ratio of -1.72 and a beta of -0.12.

Institutional Investors Weigh In On Reviva Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Drive Wealth Management LLC acquired a new position in shares of Reviva Pharmaceuticals in the 4th quarter valued at about $36,000. EMC Capital Management boosted its holdings in shares of Reviva Pharmaceuticals by 142.0% during the fourth quarter. EMC Capital Management now owns 44,535 shares of the company’s stock worth $81,000 after purchasing an additional 26,134 shares during the period. Finally, Geode Capital Management LLC grew its position in Reviva Pharmaceuticals by 17.9% during the third quarter. Geode Capital Management LLC now owns 278,496 shares of the company’s stock valued at $401,000 after purchasing an additional 42,376 shares in the last quarter. 63.18% of the stock is currently owned by institutional investors and hedge funds.

About Reviva Pharmaceuticals

(Get Free Report)

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.

Read More

Receive News & Ratings for Reviva Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reviva Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.